Clincosm LogoSign in Get a demo

refractory b acute lymphoblastic leukemia

Showing 1 - 15 of 15
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia Trial

Not yet recruiting
  • Recurrent B Acute Lymphoblastic Leukemia
  • +5 more
  • Interferon Beta-1A
  • +10 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 6, 2023

Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia Trial in

Recruiting
  • Recurrent B Acute Lymphoblastic Leukemia
  • +3 more
  • Biospecimen Collection
  • +11 more
  • Birmingham, Alabama
  • +152 more
Jan 30, 2023

Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia Trial

Not yet recruiting
  • Recurrent Acute Myeloid Leukemia
  • +7 more
  • Anti-CD123 ADC IMGN632
  • +7 more
  • (no location specified)
Dec 28, 2022

Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive, Philadelphia Chromosome Positive Trial in Monrovia,

Recruiting
  • Blasts 5 Percent or More of Bone Marrow Nucleated Cells
  • +4 more
  • ADCT-602
  • Monrovia, California
  • +1 more
Dec 7, 2022

Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Tumor Trial in

Recruiting
  • Recurrent Acute Leukemia
  • +16 more
  • Duarte, California
    City of Hope Medical Center
Nov 22, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +15 more
  • Anti-CD19/CD20/CD22 CAR T-Cells
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 4, 2022

Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia

Recruiting
  • Recurrent B Acute Lymphoblastic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 2, 2022

Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia Trial in

Terminated
Has Results
  • Philadelphia Chromosome Negative
  • +2 more
  • Blinatumomab
  • +11 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 3, 2022

Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia

Recruiting
  • Recurrent B Acute Lymphoblastic Leukemia
  • +3 more
  • Blinatumomab
  • +2 more
  • New Haven, Connecticut
  • +6 more
Jul 9, 2022

Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic

Terminated
Has Results
  • Recurrent B Acute Lymphoblastic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Apr 28, 2022

B-cell Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin
Apr 4, 2022

Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5

Withdrawn
  • Allogeneic Hematopoietic Stem Cell Transplantation Recipient
  • +7 more
  • Inotuzumab Ozogamicin
  • +2 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jan 13, 2022

B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic

Terminated
  • B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged
  • +16 more
  • Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
May 28, 2021

Dual-target CAR-T Cells, B ALL, Relapse Trial in Shenzhen (Dual target CAR-T cell therapy)

Unknown status
  • Dual-target CAR-T Cells
  • +3 more
  • Dual target CAR-T cell therapy
  • Shenzhen, Guangdong, China
    Shenzhen University General hospital
Jan 23, 2021

Refractory B Acute Lymphoblastic Leukemia, Relapse B Acute Lymphoblastic Leukemia Trial in Xi'an (Dual Specificity CD19 and CD22

Withdrawn
  • Refractory B Acute Lymphoblastic Leukemia
  • Relapse B Acute Lymphoblastic Leukemia
  • Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
  • Xi'an, Shaanxi, China
    Second Affiliated Hospital of Xi'an Jiaotong University
Nov 3, 2020